Stable isotope labeled compounds are widely used as diagnostic probes in medicine. These diagnostic stable isotope probes are now being expanded in their scope, to provide precise indications of the presence or absence of etiologically significant change in metabolism due to a specific disease. This concept exploits a labeled tracer probe that is a specifically designed substrate of a "gateway" enzyme in a discrete metabolic pathway, whose turnover can be measured by monitoring unidirectional precursor product mass flow. An example of such a probe is the 13 C-urea breath test, where labeled urea is given to patients with H. pylori infection. Another example of this kind of probe is used to study the tripeptide glutathione (glu-cys-gly, GSH), which is the most abundant cellular thiol, and protects cells from the toxic effects of reactive oxygen species. Within the gamma glutamyl cycle, 5-oxoproline (L-pyroglutamic acid) is a metabolite generated during GSH catabolism, and is metabolized to glutamic acid by 5-oxoprolinase. This enzyme can also utilize the substrate L-2-oxothiazolidone-4-carboxylate (OTC), to generate intracellular cysteine, which is beneficial to the cell. Thus, labeled ( 13 C) OTC would, under enzymatic attack yield cysteine and 13 CO 2, and can thus track the state and capacity of glutathione metabolism. Similarly, stable isotope labeled probes can be used to track the activity of the rate of homocysteine clearance, lymphocyte CD26, and liver CYP (cytochrome P450) enzyme activity. In the future, these applications should be able to titrate, in vivo, the characteristics of various specific enzyme systems in the body and their response to stress or infection as well as to treatment regimes.
Introduction
Isotopic tracers have been used to determine dynamic aspects of metabolism in both the intact animal as well as in isolated tissues. These tracers can be radioactive or stable, and the latter allows the use of tracers in vulnerable groups, such as pregnant women and children where radioactive tracers may pose an unacceptable medical risk. Stable isotopes of an element differ in their neutron numbers, and are, as their name suggests, non-radioactive. Thus, stable isotope tracers have been used to determine quantitative aspects of substrate metabolism, such as rates of synthesis, transformation, or degradation.
The method followed in human stable isotope tracerbased studies is to administer the labeled compound by mouth or intravenously, such that the labeled compound (tracer) mixes within the compound that is being traced (tracee) within the body. Analysis of blood samples to assess the tracee/tracer rates of appearance and disappearance over different time periods, or physiological states, as well as analysis of excreted tracer in order to quantify oxidative processes is possible with a variety of compounds [1] . However, there are several conditions that need to be met in human studies, in order to use kinetic data effectively. These include conditions like the physiological state, the steady state, as well as other technical issues such as tracer recycling. In addition, these studies are usually difficult to perform, and technically complex. Hence there is a need for simpler techniques to use, especially in clinical or field situations, where demanding protocols may not be possible to implement. Such a technique would ideally involve the non-invasive (oral) administration of tracer, and collection of labeled end products in the breath, but without losing diagnostic value in terms of sensitivity and specificity. This easily implemented design of study is now available through Anura V. Kurpad, Alfred Ajami, and Vernon R. Young the use of metabolic probes (or metaprobes), which assess the activity of specific enzymes in the body [2] and since breath sampling is being discussed here, 13 C, which is stable and safe for general usage, would be the label of choice.
The 13 C breath test
This test is based on the delivery of a 13 C-labeled substrate into the body by oral ingestion or by injection. A specific enzyme in the target tissue then selectively metabolizes the substrate such that the tracer is irreversibly released as 13 CO 2 into the body CO 2 pool [2] . The tracer is then transported to the circulation and excreted in the breath, such that a pattern of breath enrichment over time can be obtained. The enrichment of 13 CO 2 in the breath can be measured by isotope ratio mass spectrometry (IRMS), which typically would require about 10 ml of breath, which can be easily collected in a vacutainer or sealed glass tube. The enrichments that can be measured by this system are low (in a range of 0.0001 atom percent excess) with a high precision, meaning that less tracer can be administered (thus minimizing costs). From this pattern and extent of enrichment, qualitative conclusions can be reached about the presence or absence of specific enzyme activity. If the breath enrichment data is subjected to pharmacokinetic modeling which correlates the input dose to the output of tracer, a numeric index of the metabolism of the labeled substrate can be obtained [2] . This metabolic index provides some quantitative information about the handling of the labeled substrate by the body, but is not able to provide more detailed metabolic information about the pathways of metabolism of the substrate prior to oxidation. Thus, detailed information about pool sizes of the substrate, or of its fluxes into and out of different pools cannot be obtained. Nevertheless, the requirement of a complex methodology and design to obtain the latter information should not offset the potentially valuable information that the breath test can provide in studies on nutrition, body function and disease.
Commonly used breath tests
There are a number of 13 C based breath tests that are currently available to determine the metabolic status of various organ systems in the body. A classic application, in terms of the informatics that can be generated on individuals, is the use of 13 C-aminopyrine to distinguish among different degrees of liver disease affecting the hepatic P-450 demethylation of 13 C-aminopyrine and subsequent production of 13 CO 2 [3, 4] , or by the use of 13 C-methacetin [4] [5] [6] . Investigators have recently used labeled α-keto analogs of the branched-chain amino acids to probe hepatic mitochondrial function by measuring the exhalation of labeled CO 2 [7] . Other breath tests include gastric emptying using 13 C-octanoic acid [8, 9] , maldigestion using a variety of tracers such as 13 C-trioctanoin, 13 C-triolein etc [10] [11] [12] [13] , chylomicron remnant catabolism in obesity [14] and familial hypercholesterolemia [15] , fat digestion at a very young age, by the use of 13 C labeled mixed triglycerides [16, 17] and the development of specific P450 dependent enzyme systems in infants [18] .
In terms of infection, the most common breath test used is the 13 C-urea breath test, which is used to diagnose the presence of Helicobacter pylori infection in the stomach. H. pylori is a common infection in children studied in communities in Bangladesh [19] , India [20] , and Turkey [21] , for instance. High infection rates of H. pylori among newborns and young children in developing countries appear to be a major cause for chronic under-nutrition and diarrhea syndrome with failure to thrive. It has been shown the height-for-age is lower in H. pylori infected children than in uninfected children [22] . In terms of causative links, an increased incidence of gastrointestinal infections has been hypothesized as a cause of growth faltering.
In this test [23, 24] , 13 C-urea is administered orally, as a solution to drink, and the urease that is secreted by the H. pylori in the stomach acts on the labeled urea to release the label as 13 CO 2 . The 13 CO 2 then enters the body pool to be excreted in the breath immediately. Therefore, an increase in breath enrichment of 13 CO 2 immediately after ingestion of the 13 C-urea is indicative of an infection with this organism. Typically, breath samples are taken about 30 and 60 minutes after the dose, and are sufficient for a reliable diagnosis of the presence of H. pylori. Several studies are now available on the prevalence of this infection in developing countries, as well as its role in growth faltering in children. In India, based on this test, we have recently measured the prevalence of H. pylori in different age groups of children from rural and urban India, and found it to be of the order of about 50% to 85% in urban, low socioeconomic children between the ages of 6 to 16 years from North and South India ( 
The concept of a metabolic probe
In this paper, we describe the possibility of using stable isotope labeled compounds to explore specific enzymatic activity, through the use of metabolic probes, which we call 'metaprobes' [2] . Within the framework of this concept, intact organisms or humans can be studied through the oral administration of specific labeled molecules in order to characterize specific enzymatic activity through the measurement of the excre-tion pattern of the released label in breath or urine. The concept exploits the possibility of studying specifically designed substrates of specific enzymes in a metabolic pathway. The labeled substrate (input) is administered to a subject, followed by the characterization of the labeled product (output, 13 CO 2 ) of the enzyme activity in the breath, and the kinetics of the appearance of the product are calculated. A diagnostic determination of the metabolic activity of interest can be made based on the substrate-product conversion rate (input vs. output as a function of time) by the specific enzyme, by correlating to the metabolic condition of interest. The method can also allow for a non-invasive assessment of the effectiveness of a therapeutic intervention.
The term 'gateway' enzyme has been coined to mean those components of dynamic processes in the living organism whose turnover can be monitored by measuring unidirectional precursor-product mass flow [2] . In addition, for an enzyme system to qualify as a gateway that can be assessed practically, its metabolic products must be amenable to capture in a readily accessible metabolic compartment such as the breath, and be easily analyzed. The gateway enzyme should also be an indispensable part of a pathway, at which point a quantitative determination of the throughput (movement) of metabolites can be monitored. This is bound to be variable in populations, and therefore it is necessary to establish normative values of the labeled substrate-product conversion rate that is measured with the administration of the labeled substrate and measurement of the appearance of the labeled product. These normative data should also include conditions under which the enzyme system adapts or is regulated in health and disease, since the gateway enzyme would be chosen for study precisely because they straddle the boundaries of the divergent pathways of health and disease.
The term coined for the labeled substrate that measures gateway enzyme activity is 'metaprobe,' or a short form of metabolic probe [2] . This is a substrate that is acted upon by the gateway enzyme, and releases a labeled product that is immediately excreted in the breath (only breath tests are being referred to here; the product can also be excreted in the urine or be sampled in the blood). It is important that after the enzyme acts upon the labeled substrate, the labeled portion of the product ( 13 CO 2 ) is immediately excreted. Not all the labeled product is usually excreted, since there is retention of the 13 CO 2 in various body CO 2 pools, and this incomplete recovery is usually corrected for in classical 13 C-substrate kinetic studies. However, from the viewpoint of a diagnostic test, the recovery of the labeled product can be corrected for, by some assumptions of the rate of CO 2 production, and meaningful indexes of the metabolism of the labeled substrate obtained.
The structure of the 13 C labeled metaprobe would depend on the particular gateway enzyme structure and substrate biochemistry and the metabolic pathway of interest. Ideally, the metaprobe would contain what is called a 'release tag,' which is CO 2 or bicarbonate in this case, and a core component, which is that portion of the molecule that is acted on to trace the biochemical process being investigated.
A specific metabolic probe: L-2-Oxothiazolidine-4-carboxylic acid ( 13 C-OTC)
Glutathione (GSH), which is present in high concentrations in mammalian tissues, has many diverse functions related to the protection of cells [26, 27] . Low GSH levels are associated with increased oxidative damage in mitochondria [27] , and it has been suggested that aging is due to increased free radicals in the presence of low GSH levels [28, 29] . It is of interest, therefore, to study the modulation of GSH levels in health and disease.
GSH is synthesized through the γ-glutamyl cycle [30] . In this cycle ( fig. 1 ), 5-oxoprolinase is the enzyme that catalyzes the reaction converting 5-oxoproline to FIG. 1 GSH is synthesized in two steps from glutamate, cysteine, and glycine by 2 enzymes: 1) γ-glutamylcysteine synthetase and 2) GSH synthetase. GSH controls its production by negative feedback on reaction 1 (-). If γ-glutamylcysteine is not converted to GSH, it follows an alternate pathway to produce cysteine and 5-oxoproline, which is converted to glutamate via 5-oxoprolinase (reaction 3). Source: ref. 42 Glutamate + Cysteine glutamate, which is required for the first step for GSH synthesis, and a potential site for modulation of GSH synthesis [31, 32] . 5-oxoprolinase can also utilize the analogue, L-2-oxothiazolidine-4-carboxylate (OTC) to generate intracellular L-cysteine with the release of CO 2 , and the administration of OTC can prevent hepatic toxicity by exogenous or endogenous agents, by the stimulation of GSH formation [33, 34] . OTC can also be called a 'prodrug' of cysteine, since it is a cysteine precursor [35, 36] and the latter is thought to be the amino acid that is rate limiting for oxoproline and GSH synthesis [37] , and OTC has been established as an effective and relatively non-toxic cysteine delivery agent that is potentially useful in increasing intracellular GSH levels [38, 39] . Because of the efficient release of CO 2 from OTC, it is possible to measure the activity of 5-oxoprolinase indirectly, using a 5-13 C-oxoproline analog such as 13 C-OTC and then quantitating the 13 CO 2 accumulation in expired CO 2 [2] . The metabolism of OTC by 5-oxoprolinase is dependent on the availability of the natural substrate, 5-oxoproline, for this enzyme. Under conditions of adequate GSH (or basal) availability, the GSH titer is high and will inhibit the synthesis of γ-glutamylcysteine, which is formed by the action of γ-glutamylcysteine synthetase on cysteine and glutamate as well as GSH. The flux of the glutamyl precursors can shunt to form 5-oxoproline, which will be acted upon by the 5-oxoprolinase, such that an analog of OTC administered under these conditions would be metabolized to a lesser extent, resulting in a lower rate of 13 C-OTC conversion and a lower cumulative appearance of 13 CO 2 in the breath. Conversely, when GSH demand is high, γ-glutamylcysteine moves into GSH synthesis, leaving the 5-oxoprolinase pathway open for OTC metabolism and conversion to 13 CO 2 [2] and resulting in the appearance of higher amounts of 13 CO 2 in the breath. Therefore, this paradigm can delineate two conditions of adequate, and low GSH stores, and is the basis for the use of 13 C-OTC as a probe for precursor mobilization for GSH synthesis. The quantitation of 13 CO 2 in the breath can be used to generate some numerical evaluation of the metabolism of 13 C-OTC [2] . Therefore, by quantitating the appearance of the label in the breath over five hours after the dose, the mean residence time (MRT) can be calculated. The inverse of the MRT, which is equivalent to the fractional catabolic rate outside of the central compartment can then be multiplied by the dose of OTC per kilogram body weight, adjusted for insensible losses, to yield the 'metabolic rate index' (MRI, nmol.kg -1 . min -1 ) for OTC. The information that can be gleaned by the use of this test can be improved by creating a stimulation of GSH synthesis by first depleting GSH stores. It is known that therapeutic doses of acetaminophen can stimulate the turnover of the pool of cysteine available for the synthesis of GSH. This is most likely due to an increased rate of synthesis of GSH which is required to detoxify the toxic metabolite of acetaminophen [40, 41] . Thus Fukagawa et al. [42] have used the paradigm of the MRI of 13 C-OTC to indirectly assess precursor (cysteine) mobilization for GSH synthesis when GSH stores are reduced by an acute ingestion of acetaminophen. In their study, the MRI of the 13 C-OTC probe was found to be significantly higher after reduction of GSH content (or the stimulation of GSH synthesis) by acetaminophen. They also used this test to assess the difference in adaptive capacity (difference between basal and post-acetaminophen MRIs) between young and old individuals, and showed that this capacity was two times as large in the young subjects when compared to the old subjects (table 1) [42] . These data support the use of 13 C-OTC as a probe to characterize individuals who may be at risk for low GSH stores or who have an impaired capacity to synthesize GSH, demonstrating the possibility of monitoring the metabolism of an oral tracer as an index for precursor mobilization in an ubiquitous metabolic pathway. In the post-genomic era, this also assumes importance in terms of phenotyping individuals with genetic defects of differences in the enzymes of the gamma glutamyl cycle. GSH is important in clinical conditions, since patients who are not able to respond to a demand on their stores of GSH by increasing the synthesis of GSH may be at higher risk of developing hepatic injury from drugs that require GSH for their detoxification [43] . The OTC paradigm can be extended to evaluating the need for specific therapies in patients, by characterizing these patients in terms of their basal MRI and their adaptive capacity in response to a controlled insult such as that provided by acetaminophen. Thus, patients with a high basal MRI or a low stimulation score might be less likely to benefit from antioxidant and related therapies aimed at boosting the GSH pool and might be the most susceptible to harm from treatments such as chemotherapy. GSH levels are known to be decreased in several clinical conditions ranging from inflammatory bowel disease to HIV infection [44] [45] [46] [47] . GSH levels are low in plasma and other body fluids [46, 47] in HIV patients, and this is clinically significant, since there is a strong association between survival and GSH deficiency in CD4 cells in these patients [48] . It is thought that the oxidative stress induced by reactive oxygen species may contribute to the immunodeficiency in HIV infection [49, 50] , and studies have shown that there is an increased oxidative stress in HIV infection by an increase in lipid peroxidation [51] . Jahoor et al. have shown that the absolute synthesis rate and concentration of erythrocyte GSH are reduced in HIV subjects, and at least in part, this is cause by the availability of cysteine [52] . Other studies have also shown cysteine to be rate limiting for the synthesis rate and turnover of GSH in blood [53] . Therefore it is of interest to determine if the OTC metaprobe could evaluate this decrease in GSH synthesis rates, more particularly within the paradigm of an evaluation of the adaptive capacity of this process when a controlled insult by acetaminophen is administered. We evaluated the MRI of OTC under basal and stimulated conditions in 6 HIV infected patients, who were otherwise asymptomatic, and showed that the MRI (mean basal: 374.6, and mean post acetaminophen: 342.2 nmol.kg -1 .min -1 , table 1) did not change after the administration of acetaminophen. This suggests that the OTC probe can be used to evaluate the GSH synthesis capability in patients.
Other possible metaprobes
Homocystinuric patients have a propensity for arteriosclerosis, leading to myocardial infarction and stroke [54] . While transitions in lifestyle and nutrition in developing countries have led to an epidemic of cardiovascular disease in these populations [55] , epidemiological studies also suggest that an elevated plasma homocysteine is a risk factor for cardiovascular disease. Therefore, it is worthwhile to measure the homocysteine status in the body. Homocysteine is cleared from body pools due to the activity of two enzyme systems: the remethylating and the transulfurating enzymes (fig. 2 ). The former are vitamin (B 12 and folate) dependent, while the latter is pyridoxine dependent. Intervention trials with these vitamins have shown that homocysteinemia can be reduced by up to 25%, suggesting that a vitamin deficiency may be partly responsible for the elevated plasma homocysteine levels (reviewed in 55).
However, the genes coding for the enzymes that indirectly help in clearing homocysteine, may also be subject to mutations [56, 57] . In addition, the enzyme 5,10-methylene tetrahydrofolate reductase (MTHFR) that is involved in folate metabolism and in homocysteine clearance through its remethylation, is coded for by the MTHFR gene [58] . The gene for this enzyme is located on chromosome 1, and two common alleles, the C677T (thermolabile) allele, and the A1298C allele, have been described elsewhere [59] . The thermolabile variant of the MTHFR gene (C677T) has been identified as a determinant of elevated homocysteine levels which are known to be a risk factor for arterial and thrombotic vascular disease [60] . Therefore, the ultimate phenotypic expression of hyperhomocystenemia may be due to a combination of environmental and genomic effects. It is also likely that this phenotype of a high homocysteine level is a late manifestation of variations in the clearance kinetics of homocysteine. It would therefore be useful to have a dynamic assessment of the homocysteine clearance system so that earlier diagnosis and risk assessment is possible, and the effect of interventions such as vitamin supplementation can be studied effectively. In humans the measurement of remethylation and transulfuration rates of homo- Oxidation cysteine is possible through the use of a double-labeled methionine tracer infusion method [61] , but this is a technically demanding protocol to use.
At present, the measurement of homocysteine clearance by the isotope labelled metaprobe method has only been performed in animals [2] and is not available for use in humans, although this is anticipated. The metaprobe used is L-2-oxo-tetrahydro,1,3 thiazine-4-carboxilic (1-13 C) acid, which releases labelled homocysteine intracellularly, under the influence of oxoprolinase. The labelled homocysteine is then transulfurated to cysteine and 13 C-aminobutyrate. The latter, on oxidation, would release the label into the CO 2 pool, and this would then be detected in the breath. Therefore, a breath pattern of isotopic label release can be used to assess homocysteine dynamics, under different metabolic conditions, such as fasting or after ingesting a methionine load. Preliminary studies in rabbits support these projections [2] where the MRI under basal conditions was 85 ± 14 µmol.kg -1 .h -1 , which reduced to 28 ±16 µmol.kg -1 .h -1 with a methionine load. The difference between these two MRIs is a measure of the body's capacity to remove homocysteine from the intracellular pool, and therefore a measure of homocysteine clearance. The basal MRI would need to be characterized in healthy normal individuals and this database could be used as normative data for characterizing those individuals with low basal MRIs who would be at risk of developing homocysteinemia. However, at the present time, it cannot be assumed that this technique is easy to perform on an epidemiological basis.
Another possible metaprobe is based on an endopeptidase present on the lymphocyte surface, called dipeptidyl peptidase IV [61] , or the differentiation antigen CD26, which is important in lymphocyte activation and recognition [62] [63] [64] . The metaprobe gly-pro-2-aminobutyric-1-13 C (2) can evaluate the activity of this enzyme in vivo, since it would cleave off the L-2-aminobutyrate, which would transaminate [65] and then yield 13 CO 2 on subsequent decarboxylation of its ketoacid [66] . In this case, the metabolism of L-2-aminobutyrate by itself would need assessing as well, since there could be differences in the way in which this molecule is processed by different groups of individuals. This metaprobe has been assessed in a septic rat model [2] , and it has been shown that in rats with sepsis, the release of 13 CO 2 during sepsis was significantly higher. This kind of test is a surrogate for the efficiency and activation of the immune system and it is also possible to think of exploiting the same strategy for assessing the efficacy of therapeutic modalities that depend on the modulation of CD26.
The future
Breath tests have been in diagnostic medicine for a long time, and coupled with stable isotopes, have a promising future. Nonetheless, even though the methodology is available, and a number of breath tests have recently been proposed and evaluated for the measurement of intestinal function [67] [68] [69] [70] [71] , their use as a routine clinical test is still limited. These are possibly because of the relative lack of expensive mass spectrometers required to measure stable isotopic enrichments in breath as well as the technical knowledge that is necessary for their operation and the lack of standardized protocols for running these tests [72] . In addition, there is a need for appropriate cutoffs for the diagnosis of disease in specific populations [73] . There is also a lack of a normative database of normal responses to these tests. As new substrates and cheaper instrumentation for analysis are developed, it is possible that the usage of these tests will grow in diagnostic medicine, and contribute to the generation of normative data. Further, breath tests can be used for evaluating liver CYP (cytochrome P450) function, as for example, the 14 C labeled erythromycin breath test in the evaluation of liver CYP3A function [74, 75] , can offer a way to evaluate the hepatic response of individuals to some drugs. It is known that genotypic variants of liver CYP enzymes can affect cure rates of H. pylori with different drug doses [76] , and therefore, the rationale for drug dosing will also change depending on the development of easily available, quick, and non-invasive breath tests for this purpose.
